Clinical Trial

Prevalence of Liver Dysfunction in Pediatric Patients With Congenital Heart Disease at Assiut.

Study acronym: CHD
Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 27, 2025 (before its estimated February 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
Liver dysfunction is a well-documented complication in patients with congenital heart disease (CHD). The mechanisms leading to hepatic dysfunction may be multifactorial. Key risk factors for liver dysfunction in CHD include prolonged hypoxemia, high venous pressure, and prolonged duration of heart disease. While global studies have extensively explored this association, the prevalence of liver dysfunction in CHD varies, with studies reporting hepatic fibrosis in 30-40% of Fontan patients, while regional data, particularly from Egypt, remain limited. In this research we aim to determine the prevalence of biochemical and radiological hepatic abnormalities in pediatric CHD patients attending Assiut University Children's Hospital.
Trial Details
NCT Number NCT07144501
Lead Sponsor Assiut University
Conditions Congenital Heart Disease, Liver Dysfunction
Enrollment 40 participants
Start Date 2025-09-15
Primary Completion 2026-02-15 (estimated)
Study Completion 2026-03-15 (estimated)
Updated on ClinicalTrials.gov 2025-08-27